2025-03-12 12:50:43
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Suven Life Sciences Ltd Q3FY23 consolidated loss increases to Rs. 51.11 crores
Posted On : 2023-02-02 15:49:25( TIMEZONE : IST )
Suven Life Sciences Limited has reported Consolidated financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 5.2073 crores during the period ended December 31, 2022 as compared to Rs. 4.5926 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. -51.1152 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. -23.1815 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. -2.90 for the period ended December 31, 2022 as compared to Rs. -1.51 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹5.2073 crs | ₹4.5926 crs |  13.38% |
| Net Profit | ₹-51.1152 crs | ₹-23.1815 crs |  120.50% |
| EPS | ₹-2.90 | ₹-1.51 | 92.05% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.5.2073 crores during the period ended December 31, 2022 as compared to Rs.4.5738 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.-51.1152 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.-33.6903 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.-2.90 for the period ended December 31, 2022 as compared to Rs.-2.50 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹5.2073 crs | ₹4.5738 crs | 13.85% |
| Net Profit | ₹-51.1152 crs | ₹-33.6903 crs | 51.72% |
| EPS | ₹-2.90 | ₹-2.50 | 16.00% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.13.7749 crores during the 9 Months period ended December 31, 2022 as compared to Rs.9.1063 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.-90.6229 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.-101.1970 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.-5.46 for the 9 Months period ended December 31, 2022 as compared to Rs.-7.51 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹13.7749 crs | ₹9.1063 crs | 51.27% |
| Net Profit | ₹-90.6229 crs | ₹-101.1970 crs |  10.45% |
| EPS | ₹-5.46 | ₹-7.51 | 27.30% |
Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 61.95 as compared to the previous close of Rs. 61.80. The total number of shares traded during the day was 17905 in over 427 trades.
The stock hit an intraday high of Rs. 63.00 and intraday low of 60.95. The net turnover during the day was Rs. 1112480.00.
